Načítá se...
Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
Headaches and migraines continue to be a leading cause of suffering and disability. As per the Global Burden of Disease Survey conducted in 2010, the exact magnitude of the disease still is underestimated. Migraine alone continues to rank seventh as a cause of disability. Various therapeutic modalit...
Uloženo v:
| Vydáno v: | J Anaesthesiol Clin Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer - Medknow
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7047699/ https://ncbi.nlm.nih.gov/pubmed/32174669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/joacp.JOACP_3_19 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|